Categories: News

MAXISIQ Wins Prototype Project for the Small Cell Tactical LTE/5G Architecture with the Naval Air Warfare Center Weapons Division

AUSTIN, Texas, Sept. 2, 2025 /PRNewswire/ — MAXISIQ, a leader in delivering innovative technology solutions to the Department of Defense, is excited to share we have been awarded the Prototype Project for the Small Cell Tactical LTE/5G Architecture (“SCTL5 Architecture”) with the Naval Air Warfare Center Weapons Division.

The project, awarded in collaboration with our subcontractor Nokia Federal Solutions Inc., will involve building and delivering a flexible and modern command and control capability for electromagnetic warfare systems. This will give operators more flexibility and capability during electromagnetic spectrum operations, further strengthening MAXISIQ’s support for our customer’s mission.

About MAXISIQ

MAXISIQ is a technology company that provides cutting-edge support to both federal government Clients and commercial companies in global communications, cybersecurity, artificial intelligence, and digital engineering. With a relentless focus on mission success, MAXISIQ delivers transformative technology solutions that ensure strategic and competitive advantages.  As Clients seek out smarter, faster, and more resilient systems, MAXISIQ remains the partner of choice – engineering superiority for today, and shaping the technology landscape for tomorrow.

Media Contact:
Cara Crosby
(877) 621-1818 ext. 7
400441@email4pr.com

View original content:https://www.prnewswire.com/news-releases/maxisiq-wins-prototype-project-for-the-small-cell-tactical-lte5g-architecture-with-the-naval-air-warfare-center-weapons-division-302542185.html

SOURCE MAXISIQ

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

25 minutes ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

25 minutes ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

25 minutes ago